您好，欢迎光临上海雅吉生物商城！
工作时间：9:00-18:00
全国服务热线：021-34661276
请登录免费注册 我的订单我要询价

所有产品分类

当前位置：首页 > 抗体蛋白 > 抗体> Brilliant Violet 785™ anti-human CD3 Antibod

Brilliant Violet 785™ anti-human CD3 Antibod

订购数量：
加入购物车
加入收藏夹
规格
价格库存
订购热线：021-34661276
收藏此商品
我要询价
  • 商品详情
  • 售后服务
  • 相关文献

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785? under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Brilliant Violet 785? excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Ivarsson M, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.50. PubMed
  2. Robinson GA, et al. 2021. EBioMedicine. 103243:. PubMed
  3. Tatari N, et al. 2022. Front Immunol. 13:905768. PubMed
  4. Arce Vargas F et al. 2018. Cancer cell. 33(4):649-663 . PubMed
  5. Leeansyah E, et al. 2015. PLoS Pathog. 11: 1005072. PubMed
  6. Novakova L et al. 2018. Journal of neurochemistry. 146(3):322-332 . PubMed
  7. Zhou R, et al. 2020. Immunity. S1074-7613(20)30333-2.. PubMed
  8. Karim F, et al. 2021. Elife. 10:. PubMed
  9. Myers JA, et al. 2022. JCI Insight. :. PubMed
  10. Hinterbrandner M, et al. 2021. JCI Insight. 6:e151797. PubMed
  11. Asowata OE, et al. 2021. JCI Insight. 6:. PubMed
  12. Bj?rklund &, et al. 2016. Nat Immunol. 17:451-460. PubMed
  13. Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed
  14. Wang N, et al. 2021. iScience. 24:103205. PubMed
  15. Lisovsky I, et al. 2015. J Virol. 89: 9909 - 9919. PubMed
  16. Fisher J, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.03.002. PubMed
  17. Jackson E, et al. 2017. PLoS One. 10.1371/journal.pone.0185160. PubMed
  18. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  19. Jin Y et al. 2019. Nature communications. 10(1):391 . PubMed
  20. Neff CP et al. 2018. EBioMedicine. 30:192-202 . PubMed
  21. Davis JE, et al. 2021. J Transl Med. 19:473. PubMed
  22. Nel I, et al. 2021. Diabetologia. 64(10):2306-2321. PubMed
  23. Wu X, et al. 2018. J Immunol Methods. 455:71. PubMed
  24. Moore T,et al. 2017. Cancer Immunol Immunother. . 10.1007/s00262-017-2073-0. PubMed
  25. Huber JE, et al. 2020. J Immunol. 204:1101. PubMed
  26. Li N, et al. 2021. Cell Rep Med. 2:100297. PubMed
  27. Waddington KE, et al. 2020. Front Immunol. 1.51875. PubMed
  28. Isitman G, et al. 2016. PLoS One. 11:e0164517. PubMed
  29. Thieme CJ, et al. 2020. Cell Rep Med. 1:100092. PubMed
  30. Tuong ZK, et al. 2021. Cell Rep. 37:110132. PubMed
  31. Singh A, et al. 2020. Cell Rep. 32:108153. PubMed
  32. Bradley D, et al. 2022. Nat Commun. 13:5606. PubMed
  33. Menges D, et al. 2022. Nat Commun. 13:4855. PubMed
  34. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  35. FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed
  36. Wu X, et al. 2020. Front Immunol. 1.922222222. PubMed
  37. Martinez EM, et al. 2018. SLAS Discov. 1.377083333. PubMed
  38. Abd Hamid M et al. 2019. Cancer Immunol Res. 7(8):1293-1306 . PubMed
  39. Bruno L, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.49. PubMed
  40. Ferreira-Gomes M, et al. 2021. Nat Commun. 12:1961. PubMed
  41. Dersh D, et al. 2020. Immunity. 54(1):116-131.e10. PubMed
  42. Ogongo P, et al. 2020. J Clin Invest. 130:214. PubMed
RRID
AB_11219196 (BioLegend Cat. No. 317329) AB_2563507 (BioLegend Cat. No. 317330)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org
我要询价
*联系方式：
(可以是QQ、MSN、电子邮箱、电话等，您的联系方式不会被公开)
*内容：

  • 扫码咨询微信客服

  • 扫码咨询微信客服

首页 产品专区 品牌专区 技术资讯 关于我们 付款方式 联系我们

©Copyright 上海雅吉生物科技有限公司 All Rights Reserved. ICP备案号：沪ICP备18032507号-1 技术支持：阿仪网


微信客服
扫一扫立即咨询


微信客服
扫一扫立即咨询

销售电话：

021-34661275

021-34661276

15301693058